Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Amylyx Pharmaceuticals Inc
EPS (Diluted)
Amylyx Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
EPS (Diluted)
-$1
|
CAGR 3-Years
23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$11
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Amylyx Pharmaceuticals Inc
Glance View
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2022-01-07. The firm is developing therapies for treatment paradigm for amyotrophic lateral sclerosis (ALS), and range of neurodegenerative diseases by keeping neurons alive. The firm is pursuing commercialization of its product candidate, AMX0035. AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO) also known as ursodoxicoltaurine. AMX0035 is designed to target the endoplasmic reticulum and mitochondrial-dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. AMX0035 keep neurons alive under a variety of different conditions and stresses, including in in vitro models of neurodegeneration, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress and disease-specific models of a variety of other conditions, as well as in vivo models of Alzheimer’s Disease (AD) and multiple sclerosis.
See Also
What is Amylyx Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-1.5
USD
Based on the financial report for Dec 31, 2025, Amylyx Pharmaceuticals Inc's EPS (Diluted) amounts to -1.5 USD.
What is Amylyx Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-15%
Over the last year, the EPS (Diluted) growth was 65%. The average annual EPS (Diluted) growth rates for Amylyx Pharmaceuticals Inc have been 23% over the past three years , -15% over the past five years .
